Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1

Status

Completed 12Terminated 7Withdrawn 4Recruiting 2Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Endocrine 1

Conditions

Multiple Myeloma 2Insulinoma 1Hyperinsulinism 1Congenital Hyperinsulinism 1ACTH Syndrome, Ectopic 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × pasireotide × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

NCT02780882 2018-01-26

SOM230 Ectopic ACTH-producing Tumors

Cedars-Sinai Medical Center

Phase 2 Withdrawn

ACTH Syndrome, Ectopic

NCT01329289 2016-02-12

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

University of Pittsburgh

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT01234974 2013-01-10

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Milton S. Hershey Medical Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡